Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights Nov 07, 2019
Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting Nov 06, 2019
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights Nov 04, 2019
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development Oct 28, 2019
Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma Oct 24, 2019
Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference Oct 24, 2019
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting Oct 18, 2019
Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma Oct 10, 2019
Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019 Sep 30, 2019
Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Sep 26, 2019
